The American pharmaceutical company Pfizer is in negotiations to acquire the biotechnological company Seagen, specialized in cancer treatmentsin an operation that could exceed US$30 billion, according to The Wall Street Journal (WSJ) announced on Monday.
The economic newspaper, which quotes anonymous sources, points out that the talks are in an initial phase and that there are no guarantees that an agreement will be reached.
If the acquisition is completed, Pfizer is expected to pay more than $30 billion, Seagen’s current market value, plus a premium to close its sale.
The biotechnological company already maintained contacts last year to be acquired by the pharmaceutical company Merck Sharp & Dome (MSD, known as Merck in the US and Canada)) in an operation that would have reached US$40,000 million, but which was never completed in the end. .
Seagen is known for having helped develop a new class of cancer treatments that have already been approved to treat various lymphomas and have shown promising results against other tumors in combination with other drugs.
Pfizer, which has earned billions of dollars in recent years from the sale of its covid-19 vaccines and other products, already acquired Global Blood Therapeutics in 2022 for US$5 billion and paid more than US$10 billion to gain full control of Biohaven Pharmaceutical Holdings.
EFE
